ETNB Insider Trading

Insider Ownership Percentage: 2.80%
Insider Buying (Last 12 Months): $50,235,693.75
Insider Selling (Last 12 Months): $71,149.87

89bio Insider Trading History Chart

This chart shows the insider buying and selling history at 89bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

89bio Share Price & Price History

Current Price: $6.87
Price Change: Price Decrease of -0.405 (-5.57%)
As of 04/1/2025 02:49 PM ET

This chart shows the closing price history over time for ETNB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$7.27Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for 89bio (NASDAQ:ETNB)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ETNB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$149Mbought$27MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M$0$100MTotal InflowsTotal Outflows
89bio logo
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More on 89bio

Today's Range

Now: $6.87
Low: $6.72
High: $7.24

50 Day Range

MA: $9.18
Low: $6.58
High: $11.66

52 Week Range

Now: $6.87
Low: $5.99
High: $11.84

Volume

924,223 shs

Average Volume

1,234,465 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Who are the company insiders with the largest holdings of 89bio?

89bio's top insider shareholders include:
  1. Ra Capital Management, LP (Director)
  2. Rohan Palekar (CEO)
  3. Quoc Le-Nguyen (Insider)
  4. Ryan Martins (CFO)
  5. Charles Mcwherter (Director)
  6. Edward Morrow Atkinson III (Director)
  7. Kathleen Laporte (Director)
Learn More about top insider investors at 89bio.

Who are the major institutional investors of 89bio?

89bio's top institutional shareholders include:
  1. Janus Henderson Group PLC — 15.56%
  2. Suvretta Capital Management LLC — 9.61%
  3. RTW Investments LP — 7.05%
  4. Deep Track Capital LP — 6.10%
  5. Vanguard Group Inc. — 5.36%
  6. BVF Inc. IL — 4.08%
Learn More about top institutional investors of 89bio stock.

Which institutional investors are selling 89bio stock?

In the previous quarter, ETNB stock was sold by these institutional investors:
  1. BVF Inc. IL
  2. Adage Capital Partners GP L.L.C.
  3. Pictet Asset Management Holding SA
  4. abrdn plc
  5. Two Sigma Investments LP
  6. PDT Partners LLC
  7. Steward Partners Investment Advisory LLC
  8. Two Sigma Advisers LP

Which institutional investors are buying 89bio stock?

In the previous quarter, ETNB stock was acquired by institutional investors including:
  1. Avoro Capital Advisors LLC
  2. Deep Track Capital LP
  3. Suvretta Capital Management LLC
  4. Janus Henderson Group PLC
  5. Balyasny Asset Management L.P.
  6. Vanguard Group Inc.
  7. Redmile Group LLC
  8. Rock Springs Capital Management LP
In the previous year, these company insiders have bought 89bio stock:
  1. Ra Capital Management, LP (Director)
  2. Rohan Palekar (CEO)
  3. Quoc Le-Nguyen (Insider)
Learn More investors buying 89bio stock.